Portuguese 
English 
Spanish 
4 min of reading 
0 comments 
Learn How Ozempic and Wegovy Are Driving the Economy of Denmark and Making Kalundborg a Global Hub in Drug Production!
In the last two years, the Danish company Novo Nordisk has emerged from obscurity to become one of the most valuable pharmaceutical giants in Europe. The impressive demand for its drugs Ozempic and Wegovy, used in the treatment of diabetes and obesity, has not only boosted the company’s profits but also brought significant economic impact to Denmark, particularly to the city of Kalundborg.
The Explosive Growth of Novo Nordisk After Ozempic
Recently, Novo Nordisk reported a 22% increase in its pre-tax profits, reaching the impressive figure of US$ 17.8 billion (around R$ 103.4 billion).
This growth has made the company one of the economic engines of Denmark, contributing to the increase in GDP and the creation of thousands of jobs.
-
The largest food company on the planet, JBS, has just opened a 4,000 square meter laboratory in Florianópolis to develop customized proteins that modulate muscle mass gain, immune response, and metabolic performance.
-
After nearly 30 bids and competition among industry giants, a Spanish company purchases one of the largest airports in Brazil for almost R$ 3 billion and takes over the management of Galeão in a concession that will last until 2039.
-
The Federal Revenue Service now automatically cross-references everything you declare with data from banks, credit cards, brokerage firms, and insurance companies, and any discrepancy between your income and your expenses triggers an alert in seconds.
-
Amid global tensions, Brazil blocks the United States’ proposal at the WTO and paves the way for a trade crisis and possible retaliations.
Kalundborg, located about an hour from Copenhagen, has become one of the main production centers for the pharmaceutical company.
This city is home to the huge Novo Nordisk factory, responsible for producing half of the world’s insulin and the revolutionary active ingredient semaglutide found in Ozempic and Wegovy.
Kalundborg: From Decline to Economic Renaissance
The city of Kalundborg has a long industrial history, having been a shipbuilding center and later the manufacturing location for popular Carmen Curlers in the 1960s.
However, after periods of economic decline, the region is currently experiencing a renaissance thanks to the expansion of Novo Nordisk.
Currently, the company employs 4,400 workers in the city, a number that will increase with an investment of US$ 8.6 billion (around R$ 49.9 billion), resulting in the creation of 1,250 new direct jobs and the attraction of 3,000 construction workers.
The mayor of Kalundborg, Martin Damm, emphasizes that each industrial job generates, on average, three jobs in the service sector, further boosting the local economy.
The city’s growth is reflected in the increase in tax revenue, allowing for improvements in urban infrastructure.
Plans have already been announced for the construction of new roads, a cultural center, a library, and more than 1,250 homes.
Nevertheless, challenges still persist, such as below-average performance in local schools and a high rate of childhood obesity.
The Global Race for Obesity Drugs
Novo Nordisk, historically focused on insulin production, found a new opportunity by recognizing the potential of semaglutide for weight loss.
Today, Ozempic and Wegovy are part of a class of drugs called GLP-1, which help control blood sugar levels and suppress appetite.
Since its approval in the United States in 2017, Ozempic has become the best-selling diabetes drug in the world. Wegovy, approved in 2021, is available in 13 countries and saw its sales grow by 86% in the last year.
In the U.S., where the treatment costs over US$ 1,000 per month, high demand creates a heated market, but also controversies, such as debates in Congress about high prices compared to countries like Germany.
Obesity affects around 800 million people globally, and the weight loss drug market could reach US$ 150 billion by 2030.
This outlook has generated a “gold rush” in the pharmaceutical sector, with giants like Eli Lilly competing with Novo Nordisk to meet the growing demand.
Impact on the Danish Economy
The growth of Novo Nordisk has been so significant that it accounts for half of the GDP increase in Denmark in 2023.
The pharmaceutical sector, now responsible for 20% of new jobs in the country, has also boosted exports and strengthened the Danish crown, reducing borrowing costs in the country. However, Novo Nordisk’s dominance over the Danish economy raises concerns.
There are fears that the company may become “too big” for the country, making its economy vulnerable, similar to what happened with Finland and Nokia in the past.
Experts, however, believe that Denmark has a more resilient economic structure to cope with potential setbacks. Additionally, trade tensions with the United States may pose future challenges.
The economic transformation of Kalundborg is not limited to the growth of Novo Nordisk. Initiatives like the Helix Lab, funded by the company’s philanthropic foundation, aim to train new talents in biotechnology to supply the local industrial sector.
The city has also seen an increase in the number of foreign students and entrepreneurs attracted by the economic boom. Local businesses, such as cafes and supermarkets, report significant growth in revenue, demonstrating a positive ripple effect for the region.
The owner of a cafe in Kalundborg, Shaun Gamble, sums up the transformation of the city: “It’s still at the beginning, but I can feel the change. In five years, everything will be different – and better.”
With a booming market, Novo Nordisk and Kalundborg are at the center of a global health revolution.
Seja o primeiro a reagir!